Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Blue Cross Blue Shield of Florida will begin covering the firm's ThyGenX and ThyraMir molecular thyroid tests.

The ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier are used together to diagnose thyroid nodules with indeterminate cytology. The combination testing includes the rule-in properties of next-generation sequencing of a patient's DNA and RNA, and the rule-out capabilities of a miRNA classifier, according to Interpace.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.